CytomX results beat, positive study results

CytomX Therapeutics (NASDAQ: CTMX) reported Q1 2025 financial results and significant clinical progress. The company announced positive interim data from its Phase 1 study of CX-2051, an EpCAM Antibody Drug Conjugate for advanced colorectal cancer, initiating dose expansions at 7.2, 8.6, and 10 mg/kg doses. A Phase 2 study is planned for 1H 2026. Financially, CytomX ended Q1 2025 with $79.9 million in cash, reporting revenue of $50.9 million (up from $41.5M in Q1 2024) and reduced operating expenses of $28.3 million. The company achieved a $5 million milestone payment from Astellas and extended its cash runway into Q2 2026 through cost reductions. Their pipeline includes CX-801, a PROBODY Interferon alpha-2b, currently in Phase 1 trials for melanoma.

https://www.stocktitan.net/news/CTMX/cytom-x-therapeutics-announces-first-quarter-2025-financial-results-z1ixuwvlaade.html